IP Library › Granted Patent US 10,259,866

Granted Patent B2

US 10,259,866 · App. 15/343,450 · Granted Apr 16, 2019

TDP-43 specific binding molecules

Inventors: Roger Nitsch (Zumikon, CH); Christoph Hock (Erlenbach, CH); Maria Grazia Barenco Montrasio (Schindellegi, CH); Fabio Montrasio (Schindellegi, CH); Jan Grimm (Dubendorf, CH); Jean-Luc Baeriswyl (Zurich, CH); Paul Weinreb (Andover, MA); Janaky Coomaraswamy (Zurich, CH); Omar Quintero-Monzon (Waltham, MA)

Assignees: Biogen International Neuroscience GmbH; University of Zürich

C07K16/18 A61K39/3955 A61K49/16 A61K51/1018 G01N33/6896 A61K2039/505 A61K2039/54 C07K2317/14 C07K2317/21 C07K2317/34 C07K2317/52 C07K2317/56 C07K2317/565 C07K2317/622 C07K2317/92 G01N2333/47 G01N2800/2814

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,259,866
App. No.: 15/343,450
Granted: Apr 16, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Claims (160)

1. A polynucleotide linked to a heterologous nucleic acid, wherein the polynucleotide is selected from the group consisting of:

(a) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 11, 12, and 13, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:14 binds to TAR DNA-binding protein of 43 kDa (TDP-43);

(b) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 15, 16, and 17, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 10 binds to TDP-43;

(c) a polynucleotide encoding (i) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 11, 12, and 13, respectively; and (ii) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 15, 16, and 17, respectively;

(d) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:10, wherein the VH when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 14 binds to TDP-43;

(e) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:14, wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:10 binds to TDP-43;

(f) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:10 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:14;

(g) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 131, 132, and 133, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:134 binds to TDP-43;

(h) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 135, 136, and 137, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 130 binds to TDP-43;

(i) a polynucleotide encoding (i) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 131, 132, and 133, respectively; and (ii) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 135, 136, and 137, respectively;

(j) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:130, wherein the VH when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 134 binds to TDP-43;

(k) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:134, wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:130 binds to TDP-43;

(l) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:130 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:134;

(m) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 260, 261, and 262, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:263 binds to TDP-43;

(n) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 264, 265, and 266, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 259 binds to TDP-43;

(o) a polynucleotide encoding (i) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 260, 261, and 262, respectively; and (ii) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs: 264, 265, and 266, respectively;

(p) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:259, wherein the VH when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO:263 binds to TDP-43;

(q) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:263, wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:259 binds to TDP-43; and

(r) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:259 and an immunoglobulin light chain or a fragment thereof comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:263.

2. The polynucleotide linked to a heterologous nucleic acid of claim 1 , wherein the heterologous nucleic acid is a regulatory element.

3. The polynucleotide linked to a heterologous nucleic acid of claim 2 , wherein the regulatory element is a promoter, an enhancer, a ribosome binding site, or a transcription terminator.

4. The polynucleotide linked to a heterologous nucleic acid of claim 1 , wherein the heterologous nucleic acid encodes a secretory signal peptide.

5. The polynucleotide linked to a heterologous nucleic acid of claim 4 , wherein the secretory signal peptide is a mammalian signal peptide.

6. The polynucleotide linked to a heterologous nucleic acid of claim 5 , wherein the mammalian signal peptide is from tissue plasminogen activator.

7. An isolated host cell comprising the polynucleotide linked to a heterologous nucleic acid of claim 1 .

8. The isolated host cell of claim 7 , wherein the host cell is a Chinese Hamster Ovary (CHO) cell.

9. A cDNA comprising a polynucleotide encoding a polypeptide comprising:

an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:11, 12, and 13, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:14 binds to TDP-43;

an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:15, 16, and 17, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:10 binds to TDP-43;

an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:131, 132, and 133, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:134 binds to TDP-43;

an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:135, 136, and 137, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:130 binds to TDP-43;

an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:260, 261, and 262, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:263 binds to TDP-43; or

an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:264, 265, and 266, respectively, and wherein the VL when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:259 binds to TDP-43.

10. The cDNA of claim 9 , wherein the polypeptide comprises:

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:10;

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:130;

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:259;

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:14;

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:134; or

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:263.

11. An expression vector comprising a heterologous promoter operably linked to a polynucleotide encoding a polypeptide comprising:

12. The expression vector of claim 11 , wherein the polypeptide comprises:

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:10; or

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:14.

13. The expression vector of claim 11 , wherein the expression vector is a plasmid, phage, or virus.

14. The expression vector of claim 13 , wherein the expression vector is a retrovirus.

15. The expression vector of claim 11 , wherein the heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter.

16. The expression vector of claim 11 , wherein the heterologous promoter is the cytomegalovirus immediate early promoter.

17. The expression vector of claim 11 , wherein the polypeptide comprises a signal peptide.

18. The expression vector of claim 17 , wherein the signal peptide is a heterologous signal peptide.

19. An expression vector comprising:

a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:11, 12, and 13, respectively; and a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:15, 16, and 17, respectively,

wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-human TDP-43 antibody or TDP-43-binding fragment thereof, and

wherein the expression vector is a plasmid, phage, or virus.

20. The expression vector of claim 19 , wherein the expression vector is a retrovirus.

21. The expression vector of claim 19 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:10; and the VL consists of the amino acid sequence set forth in SEQ ID NO:14.

22. The expression vector of claim 19 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

23. The expression vector of claim 19 , wherein the second polypeptide comprises a human kappa light chain constant region.

24. An isolated host cell comprising:

a first expression vector comprising a first heterologous promoter operably linked to a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:11, 12, and 13, respectively; and a second expression vector comprising a second heterologous promoter operably linked to a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:15, 16, and 17, respectively,

wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-TDP-43 antibody or human TDP-43-binding fragment thereof.

25. The isolated host cell of claim 24 , wherein the first and second heterologous promoters are a cytomegalovirus, simian virus 40, or retroviral promoter.

26. The isolated host cell of claim 24 , wherein the first and second heterologous promoters are the cytomegalovirus immediate early promoter.

27. The isolated host cell of claim 24 , wherein the first and second expression vectors are a plasmid, phage, or virus.

28. The isolated host cell of claim 24 , wherein the first and second expression vectors are a retrovirus.

29. The isolated host cell of claim 24 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:10; and the VL consists of the amino acid sequence set forth in SEQ ID NO:14.

30. The isolated host cell of claim 24 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

31. The isolated host cell of claim 24 , wherein the second polypeptide comprises a human kappa light chain constant region.

32. A method for preparing an anti-human TDP-43 antibody or human TDP-43-binding fragment thereof, the method comprising:

culturing the isolated host cell of claim 24 in a cell culture under conditions that allow for expression of the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof; and

isolating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof from the cell culture.

33. The method of claim 32 , further comprising formulating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof into a sterile pharmaceutical composition suitable for administration to a human subject.

34. The method of claim 33 , wherein the pharmaceutical composition is suitable for intravenous or subcutaneous administration.

35. The method of claim 32 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:10; and the VL consists of the amino acid sequence set forth in SEQ ID NO:14.

36. The method of claim 35 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region.

37. An expression vector comprising a heterologous promoter operably linked to a polynucleotide encoding a polypeptide comprising:

an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:131, 132, and 133, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:134 binds to TDP-43; or

38. The expression vector of claim 37 , wherein the polypeptide comprises:

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:130; or

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:134.

39. The expression vector of claim 37 , wherein the expression vector is a plasmid, phage, or virus.

40. The expression vector of claim 39 , wherein the expression vector is a retrovirus.

41. The expression vector of claim 37 , wherein the heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter.

42. The expression vector of claim 37 , wherein the heterologous promoter is the cytomegalovirus immediate early promoter.

43. The expression vector of claim 37 , wherein the polypeptide comprises a signal peptide.

44. The expression vector of claim 43 , wherein the signal peptide is a heterologous signal peptide.

45. An expression vector comprising:

a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:131, 132, and 133, respectively; and a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:135, 136, and 137, respectively,

wherein the expression vector is a plasmid, phage, or virus.

46. The expression vector of claim 45 , wherein the expression vector is a retrovirus.

47. The expression vector of claim 45 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:130; and the VL consists of the amino acid sequence set forth in SEQ ID NO:134.

48. The expression vector of claim 45 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

49. The expression vector of claim 45 , wherein the second polypeptide comprises a human kappa light chain constant region.

50. An isolated host cell comprising:

a first expression vector comprising a first heterologous promoter operably linked to a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:131, 132, and 133, respectively; and a second expression vector comprising a second heterologous promoter operably linked to a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:135, 136, and 137, respectively,

wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-TDP-43 antibody or human TDP-43-binding fragment thereof.

51. The isolated host cell of claim 50 , wherein the first and second heterologous promoters are a cytomegalovirus, simian virus 40, or retroviral promoter.

52. The isolated host cell of claim 50 , wherein the first and second heterologous promoters are the cytomegalovirus immediate early promoter.

53. The isolated host cell of claim 50 , wherein the first and second expression vectors are a plasmid, phage, or virus.

54. The isolated host cell of claim 50 , wherein the first and second expression vectors are a retrovirus.

55. The isolated host cell of claim 50 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:130; and the VL consists of the amino acid sequence set forth in SEQ ID NO:134.

56. The isolated host cell of claim 50 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

57. The isolated host cell of claim 50 , wherein the second polypeptide comprises a human kappa light chain constant region.

58. A method for preparing an anti-human TDP-43 antibody or human TDP-43-binding fragment thereof, the method comprising:

culturing the isolated host cell of claim 50 in a cell culture under conditions that allow for expression of the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof; and

isolating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof from the cell culture.

59. The method of claim 58 , further comprising formulating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof into a sterile pharmaceutical composition suitable for administration to a human subject.

60. The method of claim 59 , wherein the pharmaceutical composition is suitable for intravenous or subcutaneous administration.

61. The method of claim 58 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:130; and the VL consists of the amino acid sequence set forth in SEQ ID NO:134.

62. The method of claim 61 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region.

63. An expression vector comprising a heterologous promoter operably linked to a polynucleotide encoding a polypeptide comprising:

an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:260, 261, and 262, respectively, and wherein the VH when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:263 binds to TDP-43; or

64. The expression vector of claim 63 , wherein the polypeptide comprises:

an immunoglobulin heavy chain or fragment thereof comprising a VH with the amino acid sequence set forth in SEQ ID NO:259; or

an immunoglobulin light chain or fragment thereof comprising a VL with the amino acid sequence set forth in SEQ ID NO:263.

65. The expression vector of claim 63 , wherein the expression vector is a plasmid, phage, or virus.

66. The expression vector of claim 65 , wherein the expression vector is a retrovirus.

67. The expression vector of claim 63 , wherein the heterologous promoter is a cytomegalovirus, simian virus 40, or retroviral promoter.

68. The expression vector of claim 63 , wherein the heterologous promoter is the cytomegalovirus immediate early promoter.

69. The expression vector of claim 63 , wherein the polypeptide comprises a signal peptide.

70. The expression vector of claim 69 , wherein the signal peptide is a heterologous signal peptide.

71. An expression vector comprising:

a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:260, 261, and 262, respectively; and a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:264, 265, and 266, respectively,

wherein the expression vector is a plasmid, phage, or virus.

72. The expression vector of claim 71 , wherein the expression vector is a retrovirus.

73. The expression vector of claim 71 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:259; and the VL consists of the amino acid sequence set forth in SEQ ID NO:263.

74. The expression vector of claim 71 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

75. The expression vector of claim 71 , wherein the second polypeptide comprises a human kappa light chain constant region.

76. An isolated host cell comprising:

a first expression vector comprising a first heterologous promoter operably linked to a first polynucleotide encoding a first polypeptide comprising an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising VH complementarity determining regions (CDRs) 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:260, 261, and 262, respectively; and a second expression vector comprising a second heterologous promoter operably linked to a second polynucleotide encoding a second polypeptide comprising an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising VL CDRs 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NOs:264, 265, and 266, respectively,

wherein the immunoglobulin heavy chain or fragment thereof when paired with the immunoglobulin light chain or fragment thereof forms an anti-TDP-43 antibody or human TDP-43-binding fragment thereof.

77. The isolated host cell of claim 76 , wherein the first and second heterologous promoters are a cytomegalovirus, simian virus 40, or retroviral promoter.

78. The isolated host cell of claim 76 , wherein the first and second heterologous promoters are the cytomegalovirus immediate early promoter.

79. The isolated host cell of claim 76 , wherein the first and second expression vectors are a plasmid, phage, or virus.

80. The isolated host cell of claim 76 , wherein the first and second expression vectors are a retrovirus.

81. The isolated host cell of claim 76 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:259; and the VL consists of the amino acid sequence set forth in SEQ ID NO:263.

82. The isolated host cell of claim 76 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region.

83. The isolated host cell of claim 76 , wherein the second polypeptide comprises a human kappa light chain constant region.

84. A method for preparing an anti-human TDP-43 antibody or human TDP-43-binding fragment thereof, the method comprising:

culturing the isolated host cell of claim 76 in a cell culture under conditions that allow for expression of the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof; and

isolating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof from the cell culture.

85. The method of claim 84 , further comprising formulating the anti-human TDP-43 antibody or human TDP-43-binding fragment thereof into a sterile pharmaceutical composition suitable for administration to a human subject.

86. The method of claim 85 , wherein the pharmaceutical composition is suitable for intravenous or subcutaneous administration.

87. The method of claim 84 , wherein:

the VH consists of the amino acid sequence set forth in SEQ ID NO:259; and the VL consists of the amino acid sequence set forth in SEQ ID NO:263.

88. The method of claim 87 , wherein the first polypeptide comprises a human IgG1 heavy chain constant region and the second polypeptide comprises a human kappa light chain constant region.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016

From: NITSCH, ROGER; HOCK, CHRISTOPH

To: UNIVERSITY OF ZÜRICH

Reel/Frame 040228/0863 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016

From: GRIMM, JAN; WEINREB, PAUL; COOMARASWAMY, JANAKY; QUINTERO-MONZON, OMAR; BARENCO MONTRASIO, MARIA GRAZIA; BAERISWYL, JEAN-LUC; MONTRASIO, FABIO

To: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH

Reel/Frame 040229/0081 →

CHANGE OF NAME Recorded Nov 4, 2016

From: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH

To: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH